EUnetHTA-EMA f-t-f meeting summary 20141209, Diemen, the Netherlands
Please find below the summary of the EUnetHTA / EMA face-to-face meeting, 9 December 2015 in Diemen, the Netherlands EMA EUnetHTA Diemen meeting Summary_Final_20150302
Draft Agenda EFPIA –EUnetHTA Expert meeting with focus on rapid REAs, October 7, 2015
Draft Agenda of the EFPIA –EUnetHTA Expert meeting with focus on rapid REAs, October 7, 2015, in Diemen, Netherlands. EFPIA-EUnetHTA Expert Meeting_ October7 2015_Agenda
Joint Assessment on Ramucirumab (Cyramza®) in combination with Paclitaxel as second-line treatment for adult patients with advanced gastric or gastro-oesophageal junction adenocarcinoma
The purpose of the assessment is to evaluate Ramucirumab (Cyramza®) in combination with Paclitaxel for the treatment of gastric cancer. Final version of the assessment was published in March 2015 Below is the documentation provided by the Joint Assessment authoring team: WP5-SA-4_RAMUCIRUMAB for the treatment of gastric cancer_APPENDIX_6_INCLUDED Ramucirumab for the treatment of gastric cancer_Rapid […]
Joint Assessment on sorafenib (Nexavar®) and its use for the treatment of progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma refractory to radioactive iodine
The purpose of the assessment is to evaluate sorafenib Nexavar® and its use as a treatment of thyroid carcinoma Final version of the assessment was published in March 2015 Below is the documentation provided by the Joint Assessment authoring team: Sorafenib for the treatment of thyroid carcinoma_Rapid REA_Final_Mar 2015_0
Training course for all EUnetHTA Stakeholders, Oct. 29th, 2014
EUnetHTA Training Course for Stakeholders, Rome, 29 Oct 2014 Agenda EUnetHTA – The European network for Health Technology Assessment. Marianne Klemp, Research Director, NOKC, Norway See the presentation Key principles of HTA or What is Meant by HTA? Conor Teljeur, HIQA, Ireland See the presentation Introduction to the HTA Core Model® and core HTA information. Kristian Lampe, THL/FINOHTA See […]
Second pilot rapid assessment on ‘canagliflozin for the treatment of type 2 diabetes mellitus’
The purpose of the assessment is to evaluate canagliflozin ‘Invokana’ and its use as a treatment of type 2 diabetes mellitus. Final version of the assessment was published in February 2014 Below is the documentation provided by the Joint Assessment authoring team: Canagliflozin for the treatment of diabetes mellitus_Rapid REA_Final_Feb 2014
Joint EMA-EUnetHTA press release on the publication of results of the first European collaboration between regulators and HTA organisations
Press release – Improving contribution of regulatory ARs to HTA_20140625
HTA 2.0 Europe conference: Networking Area and Activity Station Posters
At the HTA 2.0 Europe conference’s networking area the attendees had a unique opportunity to meet and discuss with the representatives of EUnetHTA, through the six activity stations, as well as the HTA projects of the 7th Framework Research Programme (FP7). EUnetHTA Activity Stations At the six EUnetHTA Activity Stations, the attendees could learn details […]
HTA 2.0 Europe – Teaming Up for Value: Introduction and conference invitation flyer
The HTA 2.0 Europe conference conference brought the participants up-to-date on the latest developments in the interface between science and policy in European healthcare – on HTA, regulation, reimbursement, health policy, and contributing fields of research. The conference also provided many opportunities for discussions on how collaboration, defragmentation and integrative approaches can lead to improvements in healthcare systems across […]
HTA 2.0 Europe – Teaming Up for Value: Conference recordings
Please find all recordings of the conference embedded into this page above. Click on play and hear all sessions from 1-7 or use the playlist function in the upper left-hand corner to select between the 7 sessions: 1. Welcome and introduction 2. Opening plenary: HTA, regulation and policy making – Synergy in focus 3. Panel […]
